News Help Institutional access
Back to results
Bibliographic record · Consultation and access
Artículo

Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis

Mikołaj Cichoń et al · Termedia Publishing House · 2023

Open access available
Quick overview. Review the resource’s basic details, then access the content using the main button. This page shows only the information needed to identify, cite, and open the work.
Author / responsible party
Mikołaj Cichoń et al
Publisher
Termedia Publishing House
Year
2023
ISSN
0033-2526
ISSN
0033-2526
Language
English

Resource access

Open the content from the main option or choose another available source.

DOAJ DOAJ Articles
Entrar por DOAJ
Main access

Open access available

Recurso identificado como acceso abierto, sin confirmar automáticamente si es texto completo directo.
Open resource

Summary

Descripción general del contenido del recurso.

Dupilumab is a monoclonal antibody against the a subunit of the receptor for interleukin 4 and interleukin 13. It is the first biological drug registered in the world for the treatment of atopic dermatitis. Dupilumab turned out to be a milestone in the treatment of atopic dermatitis and an alternative to standard immunosuppressive drugs. In numerous multicenter studies, including real-life studies, it has been proven that dupilumab brings a significant improvement in subjective and objective clinical symptoms in atopic dermatitis. Conjunctivitis is one of the side effects of dupilumab treatment. It is estimated that it affects about 14% of patients with atopic dermatitis. The mechanisms leading to it are not yet fully understood.

How to cite

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, M. C. E. (2023). Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis. https://doi.org/10.5114/dr.2022.125683

MLA

al, Mikołaj Cichoń et. "Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis." 2023. https://doi.org/10.5114/dr.2022.125683.

Chicago

al, Mikołaj Cichoń et. 2023. "Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis.". https://doi.org/10.5114/dr.2022.125683.

Harvard

al, M. C. E. 2023, Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis, Termedia Publishing House, available at: https://doi.org/10.5114/dr.2022.125683 [Accessed 5 Aug. 2026].

Share and print

Save the record, copy its permanent link, or print it as a PDF.

Export reference

You can export the record in common formats for use in a reference manager.

RIS BibTeX

Resource details

Bibliographic information to help confirm that this is the correct material.

Title
Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis
Author / contributors
Mikołaj Cichoń et al
Publisher
Termedia Publishing House
Publication year
2023
ISSN
0033-2526
ISSN
0033-2526
Language
English

Subjects

Explore related resources through these subjects.

atopic dermatitis; dupilumab; conjunctivitis
Copied